Compare Snap On Incorporated (SNA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap On Incorporated vs GeneDx Holdings Corp — how do they compare? Snap On Incorporated trades at $377.53 (market cap $19.65B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Snap On Incorporated is far larger — about 7.7× GeneDx Holdings Corp's market cap, and Snap On Incorporated pays a 2.57% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| SNA | WGS | |
|---|---|---|
Market Cap | $19.65B | $2.56B |
Sector | Technology | Technology |
52-Week High | $419.31 | $167.51 |
52-Week Low | $324.16 | $34.51 |
Enterprise Value | $19.28B | $2.60B |
Dividend Yield | 2.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap-On Incorporated (SNA) trades at $379.88, down 0.81% with bearish technical signals but strong fundamentals. The stock shows solid profitability with 19.6% net margins and 17.58% ROE, supported by consistent earnings beats in recent quarters. Recent institutional activity shows mixed positioning while analyst consensus remains bullish with a $473 price target representing 24.5% upside potential.
SNA presents a compelling value opportunity with premium valuation metrics balanced by robust cash flow generation and dividend stability. Key risks include integration challenges from recent acquisitions and potential margin pressure from rising costs. The stock's current technical weakness may offer entry points for long-term investors seeking quality industrial exposure.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
